Business Wire

MERCK

Del
80 Years of Innovation Drives Continued Success at Merck’s Consumer Health Business

Merck’s Consumer Health business has finished 2014 with robust financial performance. Entering 2015, this year marks 80 years since the launch of Merck’s Seven Seas brand in the UK, reflecting the firm’s rich heritage of product innovation and development.

80 years of success

2015 is exactly 80 years since the launch of Merck’s Seven Seas franchise – a company originally created by a consortium of trawler owners in East Yorkshire, England to produce fish oil supplements on highest purity levels. Since its foundation in 1935, Seven Seas has become a household name, supplying a diverse range of products in more than 100 countries worldwide. The brand continues to innovate and launch even more consumer focused solutions, best demonstrated by the launch of Perfect 7 in fall 2014.

“Innovation has been a consistent force behind Merck Consumer Health’s success, including throughout the 80 years of heritage celebrated this year for Seven Seas.” said Uta Kemmerich-Keil, CEO and President of Merck’s Consumer Health business. “This has been recognized by consumers and we remain committed to meeting changing habits and preferences, as we grow our business in 2015. We are intensively listening to and learning from consumer feedback, as our financial success is reliant on constantly improving our product offer along the consumer’s desires.”

This approach has recently also resulted in external recognition for the Seven Seas brand: Seven Seas Perfect 7, an innovative and unique blend of Omega-3 oils, vitamins and minerals specifically tailored to the nutritional needs of men and women, has received a prestigious Boots Vitamin Award in the UK as the ‘newcomer of the year’ for 2014, reflecting its popularity with consumers.

The award and product performance are indicative of Merck Consumer Health’s approach to innovation. The business is driving this through its new innovation portal, www.merck-consumer-idea.com , where consumers can now provide their thoughts on how future products could help meet their health needs. In the spirit of co-creation, the portal has already begun to capture feedback on how consumers feel that existing products could be tailored more to their needs.

Integration on track

Merck’s Consumer Health business is continuing to also benefit from product integration from Merck Serono, and this year will see the full transfer of the Vitamin D supplement Vigantoletten from Merck Serono to the Consumer Health business. This product, which is also now sold in Germany in an innovative powder format (“Vigantoletten Sticks”), has made a successful transition from the prescription to over-the-counter setting marketing.

Fastest growing Merck division in 2014

In the final quarter of 2014, the Consumer Health division reported organic growth of 6.5% to € 196.9 million compared with the same period in 2013. Key brands driving this growth include Neurobion, Femibion and Floratil; key markets growing well were Brazil, Venezuela and Germany.

For the full year 2014, Consumer Health demonstrated the ongoing success of its consumer-centric business model and the consumerization of the Neurobion and Floratil brands. With organic sales growth of 5.4% up to € 766 million (2013: € 742 million) Consumer Health was the fastest growing division in the Merck Group. EBITDA pre one-time items came in at € 169 million nearly reaching the 2013 earnings level of € 172 million despite significantly higher marketing and sales investments into the strategic brands.

About Merck’s Consumer Health Business

Brands of the Consumer Health business, such as Dolo-Neurobion® , Neurobion® , Bion® , Seven Seas® , Nasivin® , and Femibion® are innovative leaders in key markets, backed by science and trusted by consumers worldwide. The Consumer Health business is with over 2,600 employees globally active in over 40 markets. Since 2014, the portfolio comprises of brands with annual total sales of about $ 1 billion. Consumer Health is a business of the Healthcare business sector within the Merck Group with global headquarters in Darmstadt, Germany. For more information please go to www.meck-consumer-health.com

All Merck Press Releases are distributed by e-mail at the same time they become available on the Merck Website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.

Merck is a leading company for innovative, top-quality high-tech products in healthcare, life science and performance materials. The company has six businesses – Merck Serono, Consumer Health, Allergopharma, Biosimilars, Merck Millipore and Performance Materials – and generated sales of around € 11.3 billion in 2014. Around 39,000 employees work for Merck in 66 countries to improve the quality of life for patients, to further the success of customers, and to help meet global challenges. Merck is the world’s oldest pharmaceutical and chemical company – since 1668, the company has stood for innovation, business success and responsible entrepreneurship. Holding an approximately 70% interest, the founding family remains the majority owner of the company to this day. Merck, Darmstadt, Germany holds the global rights to the Merck name and brand. The only exceptions are Canada and the United States, where the company operates as EMD Serono, EMD Millipore and EMD Performance Materials.

Contact:

Merck Consumer Health
Lars Atorf
Phone: +49 6151 856 3114

Link:

ClickThru

Information om Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Følg pressemeddelelser fra Business Wire

Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.

Flere pressemeddelelser fra Business Wire

FPT Proposes Public-Private Partnership Model to Develop Vietnam’s Digital Healthcare Ecosystem10.6.2025 06:17:00 CEST | Press release

Global IT services provider FPT and Pharma Group jointly hosted the Healthcare Innovation Forum - HIF 2025. The event served as a multi-stakeholder dialogue platform with a spotlight on breakthrough innovations in science, technology, and AI to accelerate healthcare advancements and drive digital transformation in public health services. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250609760138/en/ FPT Proposes Public-Private Partnership Model to Develop Vietnam’s Digital Healthcare Ecosystem The Forum was attended by Vietnam Deputy PM H.E. Le Thanh Long, key government officials, and international guests including U.S. Ambassador Marc Knapper, Swiss Ambassador Thomas Gass, former German Vice Chancellor Dr. Philipp Rösler, and representatives from Japan, Singapore, and Harvard Medical School. Vietnam Deputy PM H.E. Le Thanh Long stressed the urgent need to reform healthcare, outlining five strategies: accelerate digitaliza

China’s Center for Drug Evaluation Accepts Merck’s Application for Marketing Authorization of Pimicotinib for Treatment of Tenosynovial Giant Cell Tumor10.6.2025 06:00:00 CEST | Press release

First global filing for potentially best-in-class TGCT treatment based on strong positive data from Phase 3 MANEUVER study Potential for pimicotinib to be first systemic TGCT therapy approved in China, following recent granting of Priority Review by CDEAdditional applications planned in the US and other markets around the world Not intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) officially accepted the company’s application for marketing authorization of pimicotinib as a Class 1 innovative drug for adult patients with tenosynovial giant cell tumors (TGCT) requiring systemic treatment. The submission follows the granting of Priority Review to pimicotinib by the CDE in May for the treatment of patients with TGCT who require systemic therapy, which is expected to expedite the review process. Pimicotinib, a potentially best-in-c

KuppingerCole Recognizes Regula as One of the Innovation Leaders in Identity Verification10.6.2025 03:00:00 CEST | Press release

Regula, a global developer of forensic devices and identity verification (IDV) solutions, has made its inaugural appearance in the KuppingerCole Leadership Compass for Identity Verification 2025. Mentioned in the Innovation Leaders category, the company is recognized for its 100% in-house R&D, forensic-grade technology, global document coverage, and advanced liveness detection capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250609760424/en/ Regula’s innovative in-house technology powers fast, seamless identity checks—now recognized by KuppingerCole Analysts. Specializing in IDV and cybersecurity industry analysis, KuppingerCole forecasts that the global IDV market will grow from $18.4 billion in 2025 to $50.07 billion by 2030, driven by increasing identity fraud, compliance requirements, user expectations, and technological advancements. As identity verification rapidly shifts toward fully remote and automated e

IFF Appoints Virginia “Gina” Drosos to Board of Directors9.6.2025 23:46:00 CEST | Press release

IFF (NYSE: IFF)—a global leader in flavors, fragrances, food ingredients, health and biosciences—today announced the appointment of Gina Drosos to its board of directors, effective June 16. Drosos brings more than 30 years of executive leadership experience across the retail, consumer goods, beauty and health care industries. “We are very pleased to welcome Gina to the IFF board,” said Kevin O’Byrne, chair of the board. “Gina brings extensive relevant experience, deep consumer insights and a proven ability to drive innovation and lead with purpose, which aligns with our long-term strategy to deliver sustainable growth and value creation for all stakeholders.” Drosos most recently served as chief executive officer and a director of Signet Jewelers Ltd. (NYSE: SIG)—the world’s largest retailer of diamond jewelry—from August 2017 to November 2024. During her tenure, she led the company through a significant transformation, expanding its digital capabilities and enhancing customer experien

Vantage Data Centers Completes Industry’s First Euro-Based Data Center Asset-Backed Securitization (ABS) with €640M Transaction9.6.2025 18:00:00 CEST | Press release

Incremental green financing will drive continued, sustainable developments across the refinanced portfolio Vantage Data Centers, a leading global provider of hyperscale data center campuses, today announced it has raised €640 million in securitized term notes, marking the first-ever euro-based securitization of data center assets in Continental Europe. The transaction includes an additional €80 million in unfunded Variable Funding Notes. The Class A-2 Notes are rated A-, and the Class B Notes are rated BBB- by Standard & Poor’s and Scope Ratings. This transaction follows Vantage’s success last year with the first-ever EMEA data center ABS completed in British pound sterling. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250609592365/en/ Pictured is BER11, part of Vantage’s first Berlin campus located in Brandenburg Park. The notes will be used to refinance four data centers in Germany, two in Offenbach, Frankfurt, and two i

I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.

Besøg vores nyhedsrum
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye